Establishment Labs Releases 2021 Sustainability Review
“Our company was founded to transform the legacy of an industry through a unique commitment to women’s health and wellbeing. On the fourth anniversary of our listing on NASDAQ, we are unveiling our vision to build a new industry where we support women empowered with the freedom to make informed decisions in the journey of breast health and wellness,” said Juan José Chacón-Quirós, Founder and CEO of
Among the topics included in the 2021 Sustainability Review are:
References to the
Global Reporting Initiative(GRI) Standards for Energy Consumption, Emissions, and Health and Safety topics as well as the Sustainable Development Goals(SDGs) outlined in the United Nationsresolution ‘The 2030 Agenda’.
An assessment of the company’s ongoing environmental efforts, including the recertification of its headquarters and manufacturing facilities as carbon neutral according to the Costa Rican national program.
Highlights from the company’s efforts in promoting women’s health and well-being, including its patient advocacy efforts, its support of breast cancer awareness and breast reconstruction, the launch of Motiva Flora® and JOY® with Ergonomix2, and other programs and initiatives.
The publication of landmark breast implant surface research in Nature Biomedical Engineering demonstrating how the Motiva® SmoothSilk® surface significantly reduced foreign-body response compared to implants with high degrees of roughness or completely smooth surfaces that were included in the study.
A description of the company’s efforts to promote the development of its employees, including ensuring a safe work environment during the COVID-19 pandemic.
- A review of the company’s 2021 financial performance, the groundbreaking ceremony of its new Sulàyöm Innovation Campus, its quality and regulatory activities, and an update on post-market surveillance clinical data.
The current and previous editions of the annual review can be found on the company’s website at: https://establishmentlabs.com/corporate-sustainability/.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “intends to,” “would,” “will,” “may” or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company’s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; the effect on our business of the current